Compare · BDX vs TCMD
BDX vs TCMD
Side-by-side comparison of Becton Dickinson and Company (BDX) and Tactile Systems Technology Inc. (TCMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and TCMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 96.8x TCMD ($534.1M).
- Over the past year, BDX is down 2.2% and TCMD is up 81.1% - TCMD leads by 83.4 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 5 for TCMD).
- BDX has more recent analyst coverage (25 ratings vs 9 for TCMD).
- Company
- Becton Dickinson and Company
- Tactile Systems Technology Inc.
- Price
- -
- -
- Market cap
- $51.69B
- $534.1M
- 1M return
- +19.45%
- -15.04%
- 1Y return
- -2.22%
- +81.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 10
- 5
- Recent ratings
- 25
- 9
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Tactile Systems Technology Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest TCMD
- Amendment: SEC Form SCHEDULE 13G/A filed by Tactile Systems Technology Inc.
- Chief Executive Officer Dodd Sheri Louise sold $323,243 worth of shares (10,978 units at $29.44), decreasing direct ownership by 5% to 232,907 units (SEC Form 4)
- SEC Form 10-Q filed by Tactile Systems Technology Inc.
- Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results
- Tactile Systems Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
- Tactile Systems Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
- Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
- Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference